Favorite

EpiPen lesson 

Congressional Republicans and Democrats staged a rousing display of rage against the CEO whose company gouged a fortune from families whose kids and sometimes grownups need the lifesaving properties of the drug EpiPen.

The national fury over the fleecing of sick children by Mylan N.V., which bought the rights to the allergy antidote and jacked up the price of a dose from $57 to $600, followed by the Mylan executive's rough treatment in Congress, caused some wonder. Could Washington at long last be spurred to do something about the chief driver of staggering health care inflation?

Don't be silly. Congress will do nothing of the sort. It and successive presidents have squandered every golden opportunity, including passage of two sweeping health-reform laws, the Medicare Modernization Act of 2003 and the Patient Protection and Affordable Care Act of 2010, a.k.a. Obamacare. Like previous laws, they imposed cost-saving rules on providers and insurers, but to get anything enacted Congress gave the drug companies a pass.

Since 1995, premiums for health plans have risen four times faster than family earnings and five times faster than inflation, owing mostly to drug prices and especially those of lifesaving medicine where drug companies know the market will bear any price hike.

Government, in the persons of Congress, the Food and Drug Administration and the Department of Health and Human Services, actually assists the gouging by approving bigger prescriptions — a mandatory twin pack in the case of EpiPen — or, also in the case of EpiPen, requiring many schools to stock them for emergencies. EpiPens have a brief shelf life so they must constantly be replaced. Mylan got Congress to provide block grants to states to stock EpiPens in schools.

Insurance companies merely raise premiums to cover the soaring costs. When Congress passed Medicare coverage for drugs in 2004, it defeated attempts by a few Democrats, including East Arkansas's Marion Berry, to control drug prices. Congress even barred the government from negotiating discounts for mass usage or from acquiring drugs in Europe or Canada where prices are far lower.

As critical cancer drugs went on the market the past 15 years, prices soared. A new cancer drug may cost a patient or her insurer more than $100,000 a year. Employer and individual plans often don't cover them. Cancer drugs are a leading cause of bankruptcies.

You may remember the furor last year after the egomaniac Martin Shkreli's company bought rights to a drug for a parasitic infection that was deadly for babies and AIDS sufferers. Shkreli became a symbol of Big Pharma greed when he raised the price of the drug, which had been around for decades, from $13.50 to $750 for one tablet. Shkreli, CEO of Turing Pharmaceuticals, regretted not raising it even more because people had to buy it or probably die. There was some satisfaction when the U.S. attorney in Brooklyn had Shkreli arrested. But his arrest had nothing to do with exploiting sick people. He was charged with securities fraud because he used drug profits to pay off investors who had lost money with his hedge fund.

To understand why no one messes with pharmaceutical profits, except to complain occasionally, you only have to switch on any TV channel and watch commercials for an hour. You know who pays the freight for public discourse.

Congressmen scored some points against EpiPen's blithe chief saleswoman, CEO Heather Bresch, but in the end it was her day, not theirs. The super-polite Rep. Elijah Cummings, D-Md., asked Bresch if she could confirm that her base annual salary was $18.9 million and that the EpiPen alone brought profits of "hundreds and hundreds of millions of dollars a year" for her company. She replied sweetly, yes and yes.

While Mylan was jacking up EpiPen's price annually, Bresch's salary went from $2.4 million to $18.9 million. Mylan's income was spent on more than executive pay. It spent lavishly on ads to promote what it called "increased anaphylaxis awareness": persuading people they needed easy access to EpiPens to avert their allergic child's sudden death.

Maybe a new president and Congress will be different. Donald Trump sided with Democrats on letting Medicare and Medicaid negotiate with drug companies and buy drugs from countries with socialized medicine, but otherwise he says only that he'll solve the problem as soon as he repeals Obamacare and ends health insurance for 20 million people. Big Pharma flushed lots of money into presidential campaigns, Hillary Clinton's more than any other, but she has been more critical than others of the whopping prices of generic and new drugs. She laid out a long list of things she would do to control drug prices, including getting Congress to levy stiff fines on companies that raise prices unjustifiably and importing vital drugs from countries with high safety standards.

You read it here first. None of it will happen.

Favorite

Sign up for the Daily Update email

Speaking of EpiPen

  • The lesson of EpiPen

    September 27, 2016
    Ernest Dumas this weeks writes about the high-priced  EpiPen and it's symbolism for a Congress controlled by drug makers, as well as rising health care costs /more/
  • More »

Comments

Subscribe to this thread:

Add a comment

More by Ernest Dumas

  • No sense of decency

    July 16 had all the attributes of the day when Donald Trump approached that "tide in the affairs of men" where they take the fateful step that leads on to either good fortune in life or misery. Good fortune, you sense, is not going to be the outcome this time.
    • Jul 19, 2018
  • Punishing the poor

    It behooves nearly every generation of Arkansas political leaders to write another chapter in the enduring and simple annals of punishing the poor.
    • Jul 12, 2018
  • Supreme Republicans

    Every day's developments produce plenty of cause for hysterics, but I'm afraid the retirement of Supreme Court Justice Anthony M. Kennedy will not prove to be much cause for either the woe or jubilation of the past week.
    • Jul 5, 2018
  • More »

Readers also liked…

  • Along the civil rights trail

    A convergence of events in recent days signaled again how far we have come and how far we have yet to go in civil rights.
    • Jan 18, 2018
  • The Oval outhouse

    One thing all Americans finally can agree upon is that public discourse has coarsened irretrievably in the era of Donald Trump and largely at his instance.
    • Jan 18, 2018
  • Shrugging off sulfides

    The Arkansas Democrat-Gazette reported a shocker on its front page Sunday. The rotten-egg odor from the Koch brothers' sprawling paper plant at Crossett is still making people sick, but the state's pollution control agency is unaware of the problem.
    • Mar 29, 2018

Latest in Ernest Dumas

  • No sense of decency

    July 16 had all the attributes of the day when Donald Trump approached that "tide in the affairs of men" where they take the fateful step that leads on to either good fortune in life or misery. Good fortune, you sense, is not going to be the outcome this time.
    • Jul 19, 2018
  • Punishing the poor

    It behooves nearly every generation of Arkansas political leaders to write another chapter in the enduring and simple annals of punishing the poor.
    • Jul 12, 2018
  • Supreme Republicans

    Every day's developments produce plenty of cause for hysterics, but I'm afraid the retirement of Supreme Court Justice Anthony M. Kennedy will not prove to be much cause for either the woe or jubilation of the past week.
    • Jul 5, 2018
  • More »

Most Viewed

  • Outmatched

    It's almost proverbial to say that every bully is a coward at heart. But that's wishful thinking. In politics, many strongmen are like Vladimir Putin: ruthless, cunning and sadistic. As the world witnessed in Helsinki, a posturing blowhard like Donald Trump is simply no match for the Russian dictator.

Most Recent Comments

 

© 2018 Arkansas Times | 201 East Markham, Suite 200, Little Rock, AR 72201
Powered by Foundation